1. Home
  2. BIIB vs CINF Comparison

BIIB vs CINF Comparison

Compare BIIB & CINF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • CINF
  • Stock Information
  • Founded
  • BIIB 1978
  • CINF 1950
  • Country
  • BIIB United States
  • CINF United States
  • Employees
  • BIIB N/A
  • CINF N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • CINF Property-Casualty Insurers
  • Sector
  • BIIB Health Care
  • CINF Finance
  • Exchange
  • BIIB Nasdaq
  • CINF Nasdaq
  • Market Cap
  • BIIB 25.1B
  • CINF 23.3B
  • IPO Year
  • BIIB 1991
  • CINF N/A
  • Fundamental
  • Price
  • BIIB $155.33
  • CINF $152.16
  • Analyst Decision
  • BIIB Buy
  • CINF Buy
  • Analyst Count
  • BIIB 27
  • CINF 7
  • Target Price
  • BIIB $252.20
  • CINF $136.57
  • AVG Volume (30 Days)
  • BIIB 1.5M
  • CINF 493.9K
  • Earning Date
  • BIIB 02-11-2025
  • CINF 02-04-2025
  • Dividend Yield
  • BIIB N/A
  • CINF 2.13%
  • EPS Growth
  • BIIB 10.05
  • CINF 83.73
  • EPS
  • BIIB 11.06
  • CINF 19.47
  • Revenue
  • BIIB $9,607,500,000.00
  • CINF $12,155,000,000.00
  • Revenue This Year
  • BIIB N/A
  • CINF N/A
  • Revenue Next Year
  • BIIB N/A
  • CINF N/A
  • P/E Ratio
  • BIIB $14.04
  • CINF $7.83
  • Revenue Growth
  • BIIB N/A
  • CINF 24.39
  • 52 Week Low
  • BIIB $153.62
  • CINF $100.31
  • 52 Week High
  • BIIB $268.30
  • CINF $161.75
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 31.72
  • CINF 50.21
  • Support Level
  • BIIB $153.69
  • CINF $148.81
  • Resistance Level
  • BIIB $162.62
  • CINF $158.02
  • Average True Range (ATR)
  • BIIB 3.42
  • CINF 2.44
  • MACD
  • BIIB 0.55
  • CINF -1.27
  • Stochastic Oscillator
  • BIIB 14.14
  • CINF 25.89

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About CINF Cincinnati Financial Corporation

Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The company operates in segments: Commercial lines insurance, Personal lines insurance, and Excess and surplus lines insurance, Life insurance, and Investments. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.

Share on Social Networks: